INFI - Earnings announcements

Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months Companies to host conference call and webcast today at 8:00 a.m. ET MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno

– MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partnership in Q1 2023 – – Cash runway into 2024 with $47.2 million in cash and cash equivalents at end of Q3 2022– – Investor conference call to be held today at 8:30 AM ET – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provi

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022. To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page

– Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer (UC) patients from MARIO-275 – – MARIO-3 triple negative breast cancer (TNBC) data update on track by year end – – Further eganelisib clinical development stage gated on potential partnership – – Increased 2022 year-end cash guidance with runway extended into 2024 – – Investor conference call to be held today at 4:30 PM EDT – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarte

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9th, 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022. Conference Call & Webcast Details Date: Tuesday, August 9th   Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/ci3bx9cc Toll Free: (800) 715-9871 International: (646) 307-1963 ID Number: 303241 A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity's website a

– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer (TNBC) expected to initiate by year-end 2022 – – MARIO-P, a clinical program designed to expand eganelisib development in additional solid tumor indications, is planned to start in 3Q2022 – – Investor conference call to be held May 3, 2022 at 4:30pm EDT – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2022 financial results and provided a corporate update. "We are pleased t

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022. Conference Call & Webcast Details Date: Tuesday, May 3rd Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/prmegw6b Toll Free: (877) 316-5293 International: (631) 291-4526 ID Number: 6618485 A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity's website

– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand eganelisib development in additional solid tumor indications, expected to initiate on a rolling basis in 3Q 2022 – – Ended 2021 with ~ $81 million of cash and cash equivalents – – Mr. Sujay Kango appointed to Infinity Board of Directors – – Investor conference call to be held today at 4:30 pm EDT – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogram

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, March 29th, 2022 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2021. Conference call & Webcast Details Date: Tuesday, March 29th Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/gpu89sxf Toll Free: (877) 316-5293 International: (631) 291-4526 ID Number: 7567637 A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity's website at www.infi.com and will be available

– Encouraging data for eganelisib in both PD-L1(-) and PD-L1(+) mTNBC patients, with meaningful prolongation of PFS over IMpassion130 reference benchmark – – Updated mTNBC data to be presented at San Antonio Breast Cancer Symposium – – Encouraging data for eganelisib in mUC patients, with a 7.5 month extension of overall survival versus control arm – – Strengthened leadership team with Chief Scientific Officer, Chief Medical Officer and Board appointments – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company") today announced its third quarter 2021 financial results and provided a corporate update on eganelisib, its potentially first-in-class, oral, immuno-oncology

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, November 2nd 2021, at 4:30pm ET to report its financial results for the third quarter of 2021. Conference call & Webcast Details Date:              Tuesday, November 2 Time:              4:30 pm Eastern Time Webcast:        https://edge.media-server.com/mmc/p/rzfwipgi Toll Free:        (877) 316-5293 International:  (613) 291-4526 ID Number:    2938945 A live webcast of the

– MARIO-275 median overall survival data show combination of eganelisib with nivolumab achieves 15.4 months compared to 7.9 months on nivolumab control arm in 2L UC - - MARIO-3 TNBC early data suggest the addition of eganelisib to standard of care regimens extends progression free survival regardless of PD-L1 status with majority of patients still on treatment – - 86.8% of evaluable 1L patients with TNBC in MARIO-3 achieved tumor reduction with a total disease control rate of 84.2% – - MARIO-275 and MARIO-3 translational data demonstrated on-mechanism increased immune activation and decreased immune suppression - - KOL event scheduled for today, July 27, 8:00 am ET - Infinity Pharmaceu